Sudden cardiac death MRI: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
/* 2022 ESC Guidelines for the management of patients with ventricular arrythymias and the prevention of sudden cardiac death {{cite journal| author=Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA | display-authors=etal| title=2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. | journal=Eur Heart J | year= 2022 | volume= 43 | issue= 40 | pages= 3997-4126 | pmid=36017572 | doi=10.1093/eurheartj/ehac26... |
||
(15 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Sudden cardiac death}} | {{Sudden cardiac death}} | ||
{{CMG}} {{AE}} {{Sara.Zand}} | {{CMG}} {{AE}} {{Sara.Zand}} {{EdzelCo}} | ||
==Overview== | ==Overview== | ||
[[Cardiac]] [[magnetic resonance imaging]] ([[MRI]]) is an accurate modality for [[diagnosis]] of structural and functional causes of [[cardiac arrest]] by the evaluation of [[chamber volumes]], [[left ventricular]] and [[right ventricular]] mass, size and function, and [[regional wall motion abnormality]]. | |||
==MRI== | |||
[[Cardiac MRI]] is an accurate modality for diagnosis of structural and functional causes of [[cardiac arrest]] by the evaluation of | *[[Cardiac]] [[magnetic resonance imaging]] ([[MRI]]) is an accurate modality for [[diagnosis]] of structural and functional causes of [[cardiac arrest]] by the evaluation of [[chamber volumes]], [[left ventricular]] and [[right ventricular]] mass, size and function, and [[regional wall motion abnormality]]. <ref name="ZarebaZareba2017">{{cite journal|last1=Zareba|first1=Wojciech|last2=Zareba|first2=Karolina M.|title=Cardiac Magnetic Resonance in Sudden Cardiac Arrest Survivors|journal=Circulation: Cardiovascular Imaging|volume=10|issue=12|year=2017|issn=1941-9651|doi=10.1161/CIRCIMAGING.117.007290}}</ref> | ||
* This imaging identifies presence of [[myocardial edema]], [[infiltration]], [[fibrosis]], and [[perfusion defects]]. | |||
==2022 ESC Guidelines for the management of patients with ventricular arrythymias and the prevention of sudden cardiac death <ref name="pmid36017572">{{cite journal| author=Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA | display-authors=etal| title=2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. | journal=Eur Heart J | year= 2022 | volume= 43 | issue= 40 | pages= 3997-4126 | pmid=36017572 | doi=10.1093/eurheartj/ehac262 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=36017572 }} </ref>== | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background: Silver"|'''Recommendations for evaluation of patients presenting with newly documented ventricular arryhthmia''''' | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''''' | |||
|- | |||
| bgcolor="LemonChiffon"| | |||
* In [[patients]] with newly documented [[ventricular arrhythmia]] ([[VA]]) (frequent [[premature ventricular contractions]] ([[PVCs]]), [[non-sustained ventricular tachycardia]] ([[NSVT]])and suspicion of [[structural heart disease]] ([[SHD]]) other than [[coronary artery disease]] ([[CAD]]) after initial evaluation, a [[cardiac magnetic resonance]] ([[CMR]]) should be considered. | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background: Silver"|'''Recommendations for evaluation of sudden cardiac arrest survivors''''' | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''''' | |||
|- | |||
| bgcolor="LightGreen"| | |||
* [[Coronary imaging]] and [[CMR]] with [[late gadolinium enhancement]] ([[LGE]]) are recommended for evaluation of [[cardiac structure]] and [[function]] in all [[SCA]] survivors without a clear underlying cause. | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background: Silver"|'''Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complex-aggravated cardiomyopathy''''' | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''''' | |||
|- | |||
| bgcolor="LemonChiffon"| | |||
* In [[patients]] with suspected [[premature ventricular complex]] ([[PVC]])-induced [[cardiomyopathy]], [[cardiac magnetic resonance]] ([[CMR]]) should be considered. | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background: Silver"|'''Recommendations for evaluation of patients presenting with dilated cardiomyopathy/ hypokinetic non-dilated cardiomyopathy''''' | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class IIa]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''''' | |||
|- | |||
| bgcolor="LemonChiffon"| | |||
* [[CMR]] with [[LGE]] should be considered in [[dilated cardiomyopathy]] ([[DCM]])/[[hypokinetic non-dilated cardiomyopathy]] ([[HNDCM]]) [[patients]] for assessing the [[etiology]] and the [[risk]] of [[ventricular arryhthmia]] ([[VA]])/ [[sudden cardiac death]] ([[SCD]]). | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background: Silver"|'''Recommendations for diagnosis of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy''''' | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''''' | |||
|- | |||
| bgcolor="LightGreen"| | |||
* In [[patients]] with suspected [[arrhythmogenic right ventricular cardiomyopathy]] ([[ARVC]]), [[CMR]] is recommended. | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background: Silver"|'''Recommendations for diagnosis of ventricular arrhythmias in hypertrophic cardiomyopathy''''' | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|'''[[2022 ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]] ''([[2022 ESC Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])''''' | |||
|- | |||
| bgcolor="LightGreen"| | |||
* [[CMR]] with [[LGE]] is recommended in [[HCM]] patients for [[diagnostic workup]]. | |||
|} | |||
==2017AHA/ACC/HRS Guideline for management of [[sudden cardiac arrest]] and [[ventricular arrhythmia]]== | ==2017AHA/ACC/HRS Guideline for management of [[sudden cardiac arrest]] and [[ventricular arrhythmia]]== | ||
<ref name="Al-KhatibStevenson2018">{{cite journal|last1=Al-Khatib|first1=Sana M.|last2=Stevenson|first2=William G.|last3=Ackerman|first3=Michael J.|last4=Bryant|first4=William J.|last5=Callans|first5=David J.|last6=Curtis|first6=Anne B.|last7=Deal|first7=Barbara J.|last8=Dickfeld|first8=Timm|last9=Field|first9=Michael E.|last10=Fonarow|first10=Gregg C.|last11=Gillis|first11=Anne M.|last12=Granger|first12=Christopher B.|last13=Hammill|first13=Stephen C.|last14=Hlatky|first14=Mark A.|last15=Joglar|first15=José A.|last16=Kay|first16=G. Neal|last17=Matlock|first17=Daniel D.|last18=Myerburg|first18=Robert J.|last19=Page|first19=Richard L.|title=2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death|journal=Circulation|volume=138|issue=13|year=2018|issn=0009-7322|doi=10.1161/CIR.0000000000000549}}</ref> | |||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
Line 25: | Line 87: | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Latest revision as of 18:13, 22 July 2023
Sudden cardiac death Microchapters |
Diagnosis |
---|
Sudden cardiac death MRI On the Web |
American Roentgen Ray Society Images of Sudden cardiac death MRI |
Risk calculators and risk factors for Sudden cardiac death MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Zand, M.D.[2] Edzel Lorraine Co, DMD, MD[3]
Overview
Cardiac magnetic resonance imaging (MRI) is an accurate modality for diagnosis of structural and functional causes of cardiac arrest by the evaluation of chamber volumes, left ventricular and right ventricular mass, size and function, and regional wall motion abnormality.
MRI
- Cardiac magnetic resonance imaging (MRI) is an accurate modality for diagnosis of structural and functional causes of cardiac arrest by the evaluation of chamber volumes, left ventricular and right ventricular mass, size and function, and regional wall motion abnormality. [1]
- This imaging identifies presence of myocardial edema, infiltration, fibrosis, and perfusion defects.
2022 ESC Guidelines for the management of patients with ventricular arrythymias and the prevention of sudden cardiac death [2]
Recommendations for evaluation of patients presenting with newly documented ventricular arryhthmia |
Class IIa (Level of Evidence: C) |
|
Recommendations for evaluation of sudden cardiac arrest survivors |
Class I (Level of Evidence: B) |
|
Recommendations for the management of patients with premature ventricular complex-induced or premature ventricular complex-aggravated cardiomyopathy |
Class IIa (Level of Evidence: C) |
|
Recommendations for evaluation of patients presenting with dilated cardiomyopathy/ hypokinetic non-dilated cardiomyopathy |
Class IIa (Level of Evidence: B) |
|
Recommendations for diagnosis of ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy |
Class I (Level of Evidence: B) |
|
Recommendations for diagnosis of ventricular arrhythmias in hypertrophic cardiomyopathy |
Class I (Level of Evidence: B) |
|
2017AHA/ACC/HRS Guideline for management of sudden cardiac arrest and ventricular arrhythmia
Class IIa (Level of Evidence: C) |
|
References
- ↑ Zareba, Wojciech; Zareba, Karolina M. (2017). "Cardiac Magnetic Resonance in Sudden Cardiac Arrest Survivors". Circulation: Cardiovascular Imaging. 10 (12). doi:10.1161/CIRCIMAGING.117.007290. ISSN 1941-9651.
- ↑ Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA; et al. (2022). "2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death". Eur Heart J. 43 (40): 3997–4126. doi:10.1093/eurheartj/ehac262. PMID 36017572 Check
|pmid=
value (help). - ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.